Vericel’s 3Q19 grow was attributable to continued strong demand for MACI, and the company expects to maintain double-digit growth in the years ahead.
RTI Surgical’s integration of Paradigm progressed slower than expected in 3Q19, leading to softer sales of coflex and a 2019 revenue guidance reduction.
Conformis’ 3Q19 sales declined in the mid-single digits due to continuing coverage denials from Aetna. An updated policy ruling is expected by year-end.